SciELO - Scientific Electronic Library Online

vol.86 número1The efficacy of a generic doxycycline tablet in the treatment of canine monocytic ehrlichiosisOverview of the perceived risk of transboundary pig diseases in South Africa índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados

  • En proceso de indezaciónCitado por Google
  • En proceso de indezaciónSimilares en Google


Journal of the South African Veterinary Association

versión On-line ISSN 2224-9435
versión impresa ISSN 1019-9128


MCLEAN, Joanne L.  y  LOBETTI, Remo G.. Use of the melanoma vaccine in 38 dogs: The South African experience. J. S. Afr. Vet. Assoc. [online]. 2015, vol.86, n.1, pp.1-4. ISSN 2224-9435.

The commercially available vaccine Oncept® is indicated for the management of dogs with stage II or III oral melanoma after local control has been achieved. Survival times in dogs with both oral and digit melanoma have been shown to be significantly increased following vaccination. This retrospective study was designed to document the investigators' experiences with Oncept® vaccine when used as an adjunct therapy for treatment of stage II-IV oral, digit and malignant melanoma of other sites after local control had been achieved in dogs presented to a South African specialist referral veterinary practice. Thirty-eight dogs diagnosed with melanoma (25 oral, 6 digit and 7 infiltrative at various other sites) underwent a combination of surgical excision and Oncept® vaccination. At the end of the study period there were 16 live and 22 dead dogs; median survival time of the live dogs was 29 months (range 2-46 months) versus 8 months (range 2-16 months) for those that died from progressive disease. This study showed that by using a combination of surgical excision and vaccination with Oncept® survival times in dogs with malignant melanoma of the oral cavity, digit and other sites can be increased significantly.

        · texto en Inglés     · Inglés ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons